Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 11/20 | 0.51 |
| ▸ | GUCY1A2 | P33402 | 11/20 | 0.51 |
| ▸ | GUCY1A1 | Q02108 | 11/20 | 0.51 |
| ▸ | GUCY1B1 | Q02153 | 11/20 | 0.51 |
| ▸ | BUB1 | O43683 | 6/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15075373 | 0.93 | GUCY1B2 (0.53) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL15075440 | 0.84 | GUCY1B2 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL16178608 | 0.82 | BUB1 (0.66) | BUB1 | |
| SCHEMBL16324219 | 0.81 | GUCY1B2 (0.45) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL3437391 | 0.81 | GUCY1B2 (0.80) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL18405059 | 0.79 | GUCY1B2 (0.46) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL15056127 | 0.79 | GUCY1B2 (0.41) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL15075385 | 0.77 | BUB1 (0.50) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL16806907 | 0.76 | GUCY1B2 (0.64) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL16807001 | 0.76 | GUCY1B2 (0.55) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794596-B1 | SUBSTITUTED BENZYLPYRAZOLES | BAYER IP GMBH (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-2794596-B1 | SUBSTITUTED BENZYLPYRAZOLES | BAYER IP GMBH (DE) | 2017-05-31 | — | — | EP | disclosed |
| US-9643953-B2 | Substituted benzylpyrazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-05-09 | — | — | US | disclosed |
| US-9643953-B2 | Substituted benzylpyrazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-05-09 | — | — | US | disclosed |
| US-9643953-B2 | Substituted benzylpyrazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-05-09 | — | — | US | disclosed |
| US-9422268-B2 | — | — | 2016-08-23 | — | — | US | disclosed |
| US-9422268-B2 | — | — | 2016-08-23 | — | — | US | disclosed |
| US-9422268-B2 | — | — | 2016-08-23 | — | — | US | disclosed |
| US-20140315934-A1 | SUBSTITUTED BENZYLPYRAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-23 | — | — | US | disclosed |
| US-20140315934-A1 | SUBSTITUTED BENZYLPYRAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-23 | — | — | US | disclosed |
| US-20140315934-A1 | SUBSTITUTED BENZYLPYRAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-23 | — | — | US | disclosed |
| WO-2013092512-A1 | SUBSTITUTED BENZYLPYRAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315934-A1 | SUBSTITUTED BENZYLPYRAZOLES | CYP3A43, CYP3A7, ABCB1 | GUCY1B2 1320/4885GUCY1A2 1589/4885GUCY1A1 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.